CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations

被引：0
|
作者：
Amiri, Payman [1 ]
Aikawa, Mina E. [1 ]
Dove, Jeff [1 ]
Stuart, Darrin D. [1 ]
Poon, Daniel [1 ]
Pick, Teresa [1 ]
Ramurthy, Savithri [1 ]
Subramanian, Sharadha [1 ]
Levine, Barry [1 ]
Costales, Abran [1 ]
Harris, Alex [1 ]
Paul, Renhow [1 ]
机构：
[1] Chiron Corp, Emeryville, CA 94608 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4855
引用
收藏
页数：2
相关论文
共 24 条
  • [1] Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF
    Emuss, V
    Garnett, M
    Mason, C
    Marais, R
    CANCER RESEARCH, 2005, 65 (21) : 9719 - 9726
  • [2] CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models
    Venetsanakos, Eleni
    Stuart, Darrin
    Nguyen Tan
    Ye, Helen
    Salangsang, Fernando
    Aardalen, Kimberley
    Faure, Michel
    Heise, Carla
    Mendel, Dirk
    Jallal, Bahija
    CANCER RESEARCH, 2006, 66 (08)
  • [3] Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A – C-Raf
    Connor M. Blair
    Nicola M. Walsh
    Bruce H. Littman
    Frank W. Marcoux
    George S. Baillie
    BMC Cancer, 19
  • [4] REDX04988, a novel dual B-RAF/C-RAF inhibitor and a potential therapeutic for BRAF-mutant colorectal cancer
    Rainard, J.
    Testar, R.
    Poonawala, R.
    Mason, H.
    Smith, P.
    Brooke, H.
    Huart, V.
    Frith, S.
    Ahmet, J.
    Hall, J.
    Morrison, A.
    Campbell, M. A.
    Bingham, M.
    Armer, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 123 - 123
  • [5] c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
    Blasco, Rafael B.
    Francoz, Sarah
    Santamaria, David
    Canamero, Marta
    Dubus, Pierre
    Charron, Jean
    Baccarini, Manuela
    Barbacid, Mariano
    CANCER CELL, 2011, 19 (05) : 652 - 663
  • [6] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Mesfer Al Shahrani
    Mohammad Abohassan
    Mohammad Y. Alshahrani
    Abdulrahim R. Hakami
    Prasanna Rajagopalan
    Journal of Computer-Aided Molecular Design, 2021, 35 : 1165 - 1176
  • [7] High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma
    Al Shahrani, Mesfer
    Abohassan, Mohammad
    Y. Alshahrani, Mohammad
    Hakami, Abdulrahim R.
    Rajagopalan, Prasanna
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2021, 35 (12) : 1165 - 1176
  • [8] Functional cross-talk between cAMP and ERK1/2 pathway promotes proliferation of somatotropinomas in a B-Raf and C-Raf dependent manner
    Jiao, Wei
    Huang, Yimin
    Sun, Wei
    Wang, Junwen
    Lei, Ting
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (04): : 4137 - 4149
  • [9] Efficacy of B-raf and MEK inhibitor on human anaplastic thyroid cancer cell lines
    Kurata, K.
    Onoda, N.
    Noda, S.
    Kashiwagi, S.
    Asano, Y.
    Takashima, T.
    Hirakawa, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S566 - S566
  • [10] Proliferation Arrest in B-Raf Mutant Melanoma Cell Lines upon MAPK Pathway Activation
    Houben, Roland
    Ortmann, Sonja
    Drasche, Astrid
    Troppmair, Jakob
    Herold, Marco J.
    Becker, Juergen C.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (02) : 406 - 414
123